ICER Debuts Clinical Trial Diversity Assessment Framework

 
• By Sue Sutter

The new tool provides a way of quantifying the degree of diversity by race/ethnicity, sex and age in clinical trials, but the results will not factor into the US health technology assessment body’s cost effectiveness determinations for new drugs.

House frame
ICER has developed a framework for assessing clinical trial diversity. • Source: Shutterstock

More from Diversity & Inclusion

More from ESG